food techGraveyard archive2018–2025

Believer Meats

Believer Meats was, at its peak, one of the most credible bets in cultivated meat — an Israeli-founded company that had done the two hardest things in the industry and still died. Founded in 2018 as Future Meat Technologies by Hebrew University professor Yaakov Nahmias, it raised more than $387 million from backers including Tyson, ADM, and S2G Ventures, rebranded to Believer in 2022, and set out to prove cultured chicken could be made cheaply at scale. In 2025 it cleared the FDA with a 'No Questions' safety letter and finished a Wilson, North Carolina plant billed as one of the world's largest cultivated-meat facilities, cleared by the USDA. Then the money ran out.

Years active

2018–2025

Total raised

$387M

Peak headcount

150

From a Jerusalem lab to a cost-curve bet

Believer began in 2018 as Future Meat Technologies, spun out of the Hebrew University of Jerusalem by biomedical engineering professor Yaakov Nahmias. Where much of the young cultivated-meat field chased beef and celebrity demos, Nahmias fixed on the least glamorous, most decisive variable: cost. The company's core claim was a fermentation-and-cell-culture process that could drive the price of cultured chicken toward parity with conventional poultry, and it published aggressive cost-per-pound targets that made it a favorite of investors betting the whole category on a manufacturing-economics breakthrough rather than a taste one. It built a pilot line in Rehovot, Israel, and framed itself less as a food brand than as a scale-up engineering problem.

Capital, a rebrand, and a factory in North Carolina

Money followed the thesis. A $347 million round in December 2021 — one of the largest ever in cultivated meat at the time — drew in food-industry strategics including Tyson Foods and ADM alongside S2G Ventures and others, pushing lifetime funding past $387 million. In 2022 the company rebranded from Future Meat to Believer Meats, signaling a shift from lab credibility to consumer ambition. Its centerpiece was a production facility in Wilson, North Carolina, announced as one of the largest cultivated-meat plants in the world and designed to produce tens of thousands of pounds of cultured chicken a year. It was the physical embodiment of the cost-at-scale bet: prove the unit economics in a real factory, then flood the market.

Winning the regulatory game — too slowly

In 2025 Believer collected the credentials most of its peers could only aspire to. The US FDA issued a 'No Questions' letter accepting the safety of its cultured chicken, and the USDA cleared the Wilson facility — the regulatory double-clearance that, in theory, opened the door to US commercial sales. But the path there had taken far longer than planned. The FDA review stretched more than a year past expectations; the war in Gaza pulled Israeli R&D staff into extended reserve duty, delaying trials; and the North Carolina build ran over, with projected costs climbing from roughly $138 million toward $154 million. Every month of delay was a month of burn against a category whose investor enthusiasm was rapidly cooling.

The raise that never closed

By late 2025 the company was out of runway and hunting for an eleventh-hour raise. Cultivated meat had fallen deeply out of favor — public comparables had cratered, several peers had shut or pivoted, and state-level bans on lab-grown meat had spooked backers. At a November town hall, staff were told a rescue financing was being pursued. It did not materialize. Compounding the crisis, contractor Gray Construction filed a roughly $35 million lawsuit alleging unpaid bills on the Wilson plant — which Believer itself later characterized as 'the straw that broke the camel's back.' A finished factory it could not afford to run became a liability rather than an asset.

Lights out with the plant still new

Around December 1, 2025, Believer Meats ceased operations and laid off nearly its entire workforce, its global HR lead confirming the company had 'made the difficult decision to cease operations.' Subsequent bankruptcy filings revealed the company was nearly $225 million in debt; a US receiver moved to liquidate the North Carolina factory and its assets while an Israeli trustee ringfenced the underlying intellectual property. The collapse was the cleanest cautionary tale the cultivated-meat sector had produced: a company that had done everything the industry said was necessary — driven down cost claims, cleared the FDA, built and USDA-certified a flagship plant — and still could not raise the operating capital to turn any of it into a single commercial sale. Regulatory and engineering wins, Believer proved, are worth nothing without a financing market willing to fund the years of losses that scale requires.

What worked, what broke

What worked

Raised more than $387 million since 2018, including a $347 million round in December 2021 that was among the largest ever in cultivated meat, drawing strategics like Tyson Foods and ADM.
Received a US FDA 'No Questions' pre-market safety letter for its cultured chicken in 2025 — a milestone only a handful of cultivated-meat companies worldwide have achieved.
Built and won USDA clearance for a Wilson, North Carolina production facility billed as one of the largest cultivated-meat plants in the world.
Pioneered a cost-first strategy, publishing aggressive cost-per-pound targets for cultured chicken that positioned it as the category's best hope for price parity.
Spun credible deep science out of the Hebrew University of Jerusalem under founder Yaakov Nahmias, becoming a flagship of Israel's alt-protein ecosystem.

What broke

A 2025 fundraise to keep the company operating never closed, leaving it unable to run the factory it had just finished building; an eleventh-hour rescue raise pitched at a November town hall failed to materialize.
The FDA regulatory review dragged more than a year past plan, delaying commercial launch and, by the company's own account, critically impairing its ability to fundraise.
Cost overruns pushed the North Carolina plant's budget from roughly $138 million toward $154 million, deepening the capital hole.
The war in Gaza pulled key Israeli R&D staff into extended military reserve duty, further delaying trials and regulatory work.
A collapsing cultivated-meat funding market — cratered public comparables, sector-wide shutdowns, and US state bans on lab-grown meat — dried up the growth capital the business depended on.
A roughly $35 million unpaid-bill lawsuit from contractor Gray Construction, which the company called 'the straw that broke the camel's back,' pushed it into insolvency; filings later showed nearly $225 million in debt.

Sources

Obituary authored Jul 2, 2026 via Sonnet 4.5 + web_search.

What’s new

Join affiliate network